28.81
0.24 (0.84%)
| Penutupan Terdahulu | 28.57 |
| Buka | 28.82 |
| Jumlah Dagangan | 6,052 |
| Purata Dagangan (3B) | 21,940 |
| Modal Pasaran | 51,387,876 |
| Harga / Jualan (P/S) | 2.12 |
| Harga / Buku (P/B) | 3.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| Margin Keuntungan | -15.45% |
| Margin Operasi (TTM) | -17.43% |
| EPS Cair (TTM) | -2.06 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 43.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.09% |
| Nisbah Semasa (MRQ) | 0.760 |
| Aliran Tunai Operasi (OCF TTM) | 1.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 1.76 M |
| Pulangan Atas Aset (ROA TTM) | -10.90% |
| Pulangan Atas Ekuiti (ROE TTM) | -25.29% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Precipio, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.40 |
|
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. It focuses on improving cancer diagnostics, particularly hematologic malignancies. Its objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, and Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division and the Products Division. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 14.13% |
| % Dimiliki oleh Institusi | 7.46% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |